TransCode Therapeutics (RNAZ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright remains neutral on the stock and has a $3.00 price target.
Emily Bodnar has given her Buy rating due to a combination of factors that exhibit a promising outlook for TransCode Therapeutics. Preliminary results from the Phase 0 clinical study, which involved a microdose of TTX-MC138 in patients with advanced solid tumors, suggest the drug is capable of reaching metastatic cancer. The study revealed that TTX-MC138 was present in the regions of metastatic lesions, indicating the drug’s ability to reach its intended targets. Furthermore, the drug’s pharmacokinetic (PK) profile was consistent with expectations, and it remained in circulation for over 20 hours, matching predictions from Drug Metabolism and Pharmacokinetics (DMPK) modeling.
Additionally, Bodnar’s rating was influenced by successful Non-Human Primate (NHP) studies which showed long circulation and proper tissue distribution of TTX-MC138, supporting the drug’s potential efficacy in humans. The drug also demonstrated significant inhibition of miRNA-10b, its target, which further instills confidence in its potential success in human trials. Moreover, the recent positive preclinical data with TTX-RIGA, another of TransCode’s drug candidates, demonstrated significant inhibition of tumor growth, adding further weight to the potential success of the company’s overall approach. Taken together, these factors form the basis of Emily Bodnar’s Buy rating for TransCode Therapeutics.
Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, IO Biotech, and Agenus. According to TipRanks, Bodnar has an average return of -15.9% and a 24.63% success rate on recommended stocks.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
TransCode Therapeutics (RNAZ) Company Description:
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Read More on RNAZ:
- TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
- Transcode Therapeutics reports treatment of tumors using TTX-RIGA
- TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
- Transcode Therapeutics 15.7M share Secondary priced at $0.51
- TransCode Therapeutics Announces Pricing of $8 Million Public Offering
